Providence Health & Services
Quick facts
| Founded | 1859 |
|---|
Marketed products
- ACTH · Endocrinology; Immunology; Rheumatology
ACTH (adrenocorticotropic hormone) stimulates the adrenal cortex to produce and release cortisol and other corticosteroids. - cetrizine · Other
- Continuation of insulin glargine · Diabetes
Insulin glargine is a long-acting basal insulin that binds to insulin receptors to lower blood glucose by promoting glucose uptake into cells and inhibiting hepatic glucose production. - Switching to NPH insulin · Diabetes
NPH insulin is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.
Phase 2 pipeline
- Cell Infusion
- DRibble vaccine
- INBRX-106
- INCAGN01876
- INCMGA00012 · Oncology
INCMGA00012 is an anti-CTLA-4 monoclonal antibody that blocks immune checkpoint inhibition to enhance T-cell activation and anti-tumor immunity.
Phase 1 pipeline
- Anti-OX40 antibody administration
- DPV-001
- Intratumoral Ipilimumab
- KLH Day 1
- KLH Day 29
- M3T01
- MEDI0562
- tadalafil and vaccination
- Tetanus Day 1
- Tetanus Day 29
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Providence Health & Services
What are Providence Health & Services's marketed drugs?
Top marketed products include ACTH, cetrizine, Continuation of insulin glargine, Switching to NPH insulin.
When was Providence Health & Services founded?
Providence Health & Services was founded in 1859.
Related
- ACTH · Endocrinology; Immunology; Rheumatology
- cetrizine · Other
- Continuation of insulin glargine · Diabetes
- Switching to NPH insulin · Diabetes
- Sector hub: All tracked pharma companies